At the news
? NEUTRALIMPACT 5/10 8-K filed Feb 24, 2026 at 16:14 ET
Vaxcyte reported its 2025 financial results, showing increased R&D and operating expenses leading to a larger net loss, while maintaining a strong cash position of $2.44 billion. The company highlighted clinical progress on its VAX-31 vaccine program, including initiation of three Phase 3 trials and completion of enrollment in an infant Phase 2 study, along with a recent $632.5 million equity offering that strengthens its balance sheet.
- Cash, cash equivalents and investments were $2.44 billion as of December 31, 2025, down from $3.13 billion in 2024
- Completed $632.5 million equity offering in February 2026
- Net loss was $766.6 million for 2025, compared to $463.9 million in 2024
- Research and development expenses were $794.3 million for 2025, up from $476.6 million in 2024
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access